Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,779 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Conditioning Clear all
Completed Phase 2 Interventional

Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

NCT01130194
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Combination of treatment modalities
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 3 Interventional

PRP in ACLR to Prevent PTOA

NCT05412381
View directory record Official record
Conditions
Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, PRP
Interventions
platelet rich plasma (PRP) injection, placebo saline injection
Procedure
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
14 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma

NCT06617286
View directory record Official record
Conditions
Classical Hodgkin Lymphoma
Interventions
CD30 CAR T-cell
Biological
Lead sponsor
New York Medical College
Other
Eligibility
6 Years to 29 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Trial Of Double Umbilical Cord Blood Transplantation

NCT00763490
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI), Graft versus Host Disease prevention (GVHD prophylaxis), Mycophenolate Mofetil
Procedure · Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2016 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Brain Imaging Study of Opioid (Morphine) and Non-opioid (Ketorolac) Conditioning Effects

NCT01576276
View directory record Official record
Conditions
Healthy Controls
Interventions
Integrated MR-PET scan, Ketorolac
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

NCT00809276
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
Interventions
Busulfan, Fludarabine, Cytoxan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

Progressive Resistance Training for the Improvement of Physical Function

NCT04247425
View directory record Official record
Conditions
Sarcoma
Interventions
Exercise Counseling, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
15 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma

NCT00278525
View directory record Official record
Conditions
SYSTEMIC SCLERODERMA
Interventions
standard of care, stem cell transplantation
Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Up to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 2Phase 3 Interventional

Epidural Stimulation and Resistance Training After SCI

NCT04782947
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Exoskeletal assisted walking, Epidural Stimulation, Resistance Training, delayed-ES, no-Resistance training
Device · Procedure
Lead sponsor
United States Department of Defense
Federal
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 2, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

NCT02259348
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan, Thiotepa, Rituximab, Natural killer cell therapy, T-cell depleted HPC transplant, CD45RA-depleted HPC transplant
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Not listed Not applicable Interventional

Delivery of Enhance Fitness Trial

NCT05275348
View directory record Official record
Conditions
Arthritis, Rheumatoid Arthritis, Fibromyalgia, Gout, Osteoarthritis, Lupus or SLE
Interventions
Tele-Enhance Fitness, In-person Enhance Fitness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2Phase 3 Interventional

A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT03655678
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional

National Program to Overcome Pelvic Pain studY (POPPY)

NCT06778070
View directory record Official record
Conditions
Chronic Pelvic Pain Syndrome (CPPS), Chronic Pelvic Pain Syndrome, Chronic Pelvic Pain
Interventions
Pelvic floor yoga, Physical conditioning
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

NCT00301834
View directory record Official record
Conditions
Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
Interventions
alemtuzumab, busulfan, cyclosporine, fludarabine phosphate, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
San Francisco, California • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fear Conditioning Using Computer-Generated Virtual Reality

NCT00025844
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 50 Years
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Active, not recruiting Not applicable Interventional Results available

Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion

NCT05236764
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Hemophagocytic Lymphohistiocytoses, Primary Immunodeficiency Diseases, Hemoglobinopathies, Severe Aplastic Anemia, Cytopenia, Bone Marrow Failure Syndrome, Severe Chronic Active Epstein-Barr Virus Infection
Interventions
CliniMACS
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 55 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 1 Interventional

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

NCT06287944
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Daratumumab, Echocardiography, Fludarabine, Hematopoietic Cell Transplantation, Indium In 111-DOTA-Daratumumab, Melphalan, Multigated Acquisition Scan, Radionuclide Imaging, Single Photon Emission Computed Tomography, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
Biological · Procedure · Drug + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT

NCT02989844
View directory record Official record
Conditions
Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS)
Interventions
N-803
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 22, 2026, 8:40 AM EDT
Not listed Phase 1Phase 2 Interventional

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

NCT00679536
View directory record Official record
Conditions
Leukemia
Interventions
Busulfan, Fludarabine, Thymoglobulin, Total Body Irradiation
Drug · Radiation
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 23, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a High-Protein Diet and/or High-Intensity Training on Metabolic Syndrome

NCT01622634
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Sprint Interval Exercise, Higher PRO Diet, Higher CARB Diet
Behavioral · Other
Lead sponsor
University of Georgia
Other
Eligibility
30 Years to 65 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Athens, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 22, 2026, 8:40 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

NCT06851767
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions
Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells
Genetic · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional

Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes

NCT06967701
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Latent Autoimmune Diabetes in Adult (LADA), Pancreatitis
Interventions
Exercise program, Self-monitoring
Behavioral
Lead sponsor
Yale University
Other
Eligibility
30 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multi-site Animal Assisted Intervention for Children With DD and Their Family Dog

NCT04799119
View directory record Official record
Conditions
Physical Activity, Social Wellbeing
Interventions
Do As I Do (DAID) dog training
Behavioral
Lead sponsor
Oregon State University
Other
Eligibility
10 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Corvallis, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 22, 2026, 8:40 AM EDT